Cargando…
Identification of a Dual Inhibitor of Secreted Phospholipase A(2) (GIIA sPLA(2)) and SARS-CoV-2 Main Protease
The development of novel agents to combat COVID-19 is of high importance. SARS-CoV-2 main protease (M(pro)) is a highly attractive target for the development of novel antivirals and a variety of inhibitors have already been developed. Accumulating evidence on the pathobiology of COVID-19 has shown t...
Autores principales: | Theodoropoulou, Maria A., Koutoulogenis, Giorgos S., Zhang, Linlin, Akrani, Ifigeneia, Mikros, Emmanuel, Hilgenfeld, Rolf, Kokotos, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414318/ https://www.ncbi.nlm.nih.gov/pubmed/36015109 http://dx.doi.org/10.3390/ph15080961 |
Ejemplares similares
-
Progranulin inhibits phospholipase sPLA2-IIA to control neuroinflammation
por: Du, Huan, et al.
Publicado: (2023) -
2-Oxoester Phospholipase A(2) Inhibitors with Enhanced Metabolic Stability
por: Koutoulogenis, Giorgos S., et al.
Publicado: (2020) -
The Roles of sPLA(2)s in Skin Homeostasis and Disease
por: Yamamoto, Kei, et al.
Publicado: (2023) -
Discovery of AZD2716: A Novel Secreted Phospholipase
A(2) (sPLA(2)) Inhibitor for the Treatment of Coronary
Artery Disease
por: Giordanetto, Fabrizio, et al.
Publicado: (2016) -
sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor
por: Pan, Yangbin, et al.
Publicado: (2014)